Pharmacokinetics of Oral Nifedipine in Different Populations

Nifedipine disposition varies among populations. Reports on oral nifedipine pharmacokinetics show that peak plasma levels and AVC values are higher in Mexican and Japanese than in European and North American subjects. Increased nifedipine bioavailability in the nonwhite populations is likely due to nutritional habits. Certain flavonoids that inhibit the first‐pass metabolism of dihydropyridines are present in the diets of both Mexican and Japanese. Differences in phenotypes may play a role in interethnic variability.

[1]  D. Bailey,et al.  Interaction of citrus juices with felodipine and nifedipine , 1991, The Lancet.

[2]  F. Guengerich,et al.  In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. , 1990, Carcinogenesis.

[3]  S. Hosoda,et al.  Dose Dependent Effect of Diltiazem on the Pharmacokinetics of Nifedipine , 1989, Journal of clinical pharmacology.

[4]  G. Castañeda-Hernández,et al.  Pharmacokinetics of Nifedipine Slow Release Tablet in Mexican Subjects: Further Evidence for an Oxidation Polymorphism , 1989, Journal of clinical pharmacology.

[5]  J. M. Rodríguez,et al.  Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. , 1989, Archivos de investigacion medica.

[6]  G. Castañeda-Hernández,et al.  Pharmacokinetics of Oral Nifedipine: Relevance of the Distribution Phase , 1989, Journal of clinical pharmacology.

[7]  D. Breimer,et al.  Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. , 1988, Biochemical pharmacology.

[8]  A G Renwick,et al.  The pharmacokinetics of oral nifedipine--a population study. , 1988, British journal of clinical pharmacology.

[9]  A. Renwick,et al.  The trans-hepatic extraction of nifedipine. , 1987, British journal of clinical pharmacology.

[10]  M. Zinny,et al.  Effect of food on nifedipine pharmacokinetics , 1987, Clinical pharmacology and therapeutics.

[11]  S. Clissold,et al.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. , 1987, Drugs.

[12]  M. Kausch,et al.  Non-bioequivalence of sublingual nifedipine [letter] , 1987 .

[13]  A. Renwick,et al.  Food and nifedipine pharmacokinetics. , 1987, British journal of clinical pharmacology.

[14]  L. Lesko,et al.  Accumulation of nifedipine after multiple doses , 1986, The Journal of pharmacy and pharmacology.

[15]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[16]  P. Turner,et al.  The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers. , 1986, British journal of clinical pharmacology.

[17]  R. N. Brogden,et al.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. , 1985, Drugs.

[18]  R. Blouin,et al.  Pharmacokinetics of calcium-entry blockers. , 1985, The American journal of cardiology.

[19]  A. Renwick,et al.  The first pass metabolism of nifedipine in man. , 1984, British journal of clinical pharmacology.

[20]  M. Danhof,et al.  Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. , 1984, Biochemical pharmacology.

[21]  D. Breimer,et al.  Nifedipine: Kinetics and dynamics in healthy subjects , 1984, Clinical pharmacology and therapeutics.

[22]  J. Sommer,et al.  Pharmacokinetics and metabolism of nifedipine. , 1983, Hypertension.

[23]  V. R. Richards,et al.  Nifedipine Kinetics and Bioavailability After Single Intravenous and Oral Doses in Normal Subjects , 1983, Journal of clinical pharmacology.

[24]  J. J. Korst,et al.  Occurrence and measurement of nifedipine and its nitropyridine derivatives in human blood plasma. , 1982, Journal of chromatography.

[25]  R. Terry,et al.  Nifedipine therapy in angina pectoris: evaluation of safety and side effects. , 1982, American heart journal.

[26]  E. Vesell.  Genetic and environmental factors affecting drug disposition in man , 1977, Clinical pharmacology and therapeutics.

[27]  R. N. Brogden,et al.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. , 1991, Drugs.

[28]  D. Breimer,et al.  Nifedipine: variability in its kinetics and metabolism in man. , 1989, Pharmacology & therapeutics.

[29]  F. Guengerich.  Characterization of human microsomal cytochrome P-450 enzymes. , 1989, Annual review of pharmacology and toxicology.

[30]  D. Breimer,et al.  Nifedipine. Relationship between pharmacokinetics and pharmacodynamics. , 1987, Clinical pharmacokinetics.

[31]  R. Ziegler,et al.  Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. , 1986, American journal of nephrology.

[32]  R. F. Albach,et al.  Composition and inheritance of flavanones in citrus fruit , 1969 .